Patents Assigned to Institut National de la Sante et de la Recherche Medicale (Inserm)
-
Patent number: 11767333Abstract: The invention relates to 4-(1-hydroxy-3,4-dihydro-1H-benzo[c][1,2]oxaborinin-3-yl)benzimidamide derivatives and their use in treating diseases and conditions of the skin (for example, Netherton syndrome, rosacea, atopic dermatitis, psoriasis and itch) caused by abnormally high levels of protease activity (particularly of serine proteases such as kallikreins). In addition, the invention relates to compositions containing the derivatives and processes for their preparation.Type: GrantFiled: May 6, 2022Date of Patent: September 26, 2023Assignee: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: John Liddle, Ann Louise Walker, Gemma Victoria White, Alexis Denis, Nerina Dodic, Marie-Hélène Fouchet, Anne Bouillot
-
Publication number: 20230293478Abstract: The invention relates compound of formula (I), enantiomers, mixture of enantiomers, diastereoisomers and mixture of diastereoisomers thereof: wherein W, X, Y and Z are as defined, for use in the treatment of Acute Myeloid Leukemia (AML).Type: ApplicationFiled: May 12, 2021Publication date: September 21, 2023Applicants: Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Curie, Peter MacCallum Cancer InstituteInventors: Raphaël RODRIGUEZ, Mark DAWSON, Sylvain GARCIAZ, Tatiana CANEQUE COBO
-
Publication number: 20230293586Abstract: The invention relates to an in vitro method to generate T cell progenitors, comprising the step of culturing CD34+ cells in a medium containing TNF-alpha and/or an antagonist of the Aryl hydrocarbon/Dioxin receptor, in particular StemRegenin 1 (SR1), in presence of a Notch ligand and optionally a fibronectin fragment.Type: ApplicationFiled: April 6, 2023Publication date: September 21, 2023Applicants: Assistance Publique - Hopitaux de Paris, Fondation Imagine - Institut des Maladies Génétiques, Université Paris Cité, Institut National de la Santé et de la Recherche Médicale (INSERM)Inventors: Isabelle ANDRÉ, Marina CAVAZZANA, Kuiying MA, John TCHEN, Tayebeh-Shabi SOHEILI, Ranjita Devi MOIRANGTHEM
-
Publication number: 20230285381Abstract: The present invention relates to compounds of formula (I); for use as peripheral NMDA receptor antagonists.Type: ApplicationFiled: April 6, 2023Publication date: September 14, 2023Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITÉ PARIS-SACLAY, ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (APHP), HOPITAL MARIE LANNELONGUEInventors: Sylvia COHEN-KAMINSKY, Marc HUMBERT, Sebastien DUMAS, Gilles BRU-MERCIER, Samir MESSAOUDI, Jean-Daniel BRION, Mouad ALAMI, Gilles GALVANI
-
Patent number: 11744863Abstract: Process for preparing a heat-treated pooled human platelet lysate, said process comprising the steps of: a) Providing a pooled human platelet lysate (p HPL), b) Heat-treating the pooled human platelet lysate at a temperature of 50° C. to 70° C. during 20 to 40 minutes, c) Purifying the heat-treated pooled human platelet lysate of step b).Type: GrantFiled: June 15, 2018Date of Patent: September 5, 2023Assignees: Centre Hospitalier Regional et Universitaire De Lille (CHRU), UNIVERSITE DE LILLE 2 DROIT ET SANTE, UNIVERSITE DU LITTORAL COTE D'OPALE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), TAIPEI MEDICAL UNIVERSITYInventors: David Devos, Thierry Burnouf, Jean-christophe Devedjian, Ming-Li Chou, Flore Gouel
-
Publication number: 20230256138Abstract: The present invention relates to a biomaterial comprising: —a membrane wound patch (a), made of a nanofibrous polymeric scaffold, —a hydrogel (b) including autologous or allogenic bone marrow-derived mesenchymal stem cells, and —a bone wound patch (c) being a nanofibrous scaffold made of polymers, wherein said scaffold has a surface coated with an interrupted coating made of multilayered droplets, said multilayered droplets being droplets composed of at least one layer pair consisting of a layer of polyanions and a layer of polycations, and wherein the bone wound patch (c) further comprises a bone growth factor; wherein the hydrogel (b) is included between the membrane wound patch (a) and the bone wound patch (c).Type: ApplicationFiled: May 14, 2020Publication date: August 17, 2023Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITÉ DE STRASBOURGInventor: Nadia BENKIRANE-JESSEL
-
Patent number: 11723956Abstract: The present invention concerns a thermosensitive polymeric hydrogel comprising at least one thermosensitive copolymer, one aqueous solution, and a mucoadhesive excipient, wherein said thermosensitive polymeric hydrogel further comprises at least one immunostimulatory adjuvant and/or at least one cytokine and/or at least one chemokine and/or atleast one heat shockprotein. Another object of the invention is a thermosensitive polymeric hydrogel according to the invention for use in the treatment of tumors or metastasis in a subject having a cancer, preferably a metastatic cancer.Type: GrantFiled: August 31, 2017Date of Patent: August 15, 2023Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Université de Paris, Assistance Publique—Hopitaux de Paris, Ecole Nationale Superieure de Chimie de Paris, Universite de Versailles—St. Quentin en YvelinesInventors: Robert Malafosse, Nathalie Mignet, Vincent Boudy, Johanne Seguin, Kathia Lemdani, Claude Capron
-
Patent number: 11725183Abstract: The present invention relates to an in vitro method of culturing a segmented filamentous bacterium strain, comprising co-culturing said segmented filamentous bacterium strain with a eukaryotic host cell, wherein the culture is performed at an O2 level inferior to 5% in a rich tissue culture liquid medium containing bacterial medium components including iron. The present invention also relates to methods for genetically modifying a segmented filamentous bacterium strain comprising a step a culturing the strain in vitro.Type: GrantFiled: August 22, 2019Date of Patent: August 15, 2023Assignees: INSTITUT PASTEUR, FONDATION IMAGINE, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, UNIVERSITE PARIS CITE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Gerard Eberl, David Bikard, Pamela Schnupf, Nadine Cerf Bensussan, Valerie Gaboriau-Routhiau, Philippe Sansonetti
-
Patent number: 11713481Abstract: A process for pre-concentration and detection of at least one single-stranded nucleic acid target molecule, the process comprising the steps of generating a flow of liquid comprising at least one magnetic nanoparticle in a micro-channel and a plurality of single-stranded nucleic acid probe molecules attached to the nanoparticle, generating an alternating magnetic field in the part of the micro-channel using an electromagnet, the magnetic field having an intensity and frequency that are suitable for causing magnetic hyperthermia of the nanoparticles so as to cause denaturing of the duplex formed by the single-stranded nucleic acid target molecule and the single-stranded nucleic acid probe molecule, and detecting the single-stranded target molecule dispersed in the liquid.Type: GrantFiled: October 5, 2018Date of Patent: August 1, 2023Assignees: Centre National de la Recherche Scientifique (CNRS), Institut National de La Sante et de la Recherche Medicale (INSERM), Sorbonne UniversiteInventors: Marie-Charlotte Horny, Jean-Michel Siaugue, Vincent Dupuis, Mathieu Lazerges, Jean Gamby
-
Patent number: 11708364Abstract: The present invention concerns a compound of formula (I), or one of its pharmaceutically acceptable salts, especially for use as inhibitors of the ERK kinase activity in particular ERK2 activity, it also concerns prodrugs of these compounds.Type: GrantFiled: March 29, 2021Date of Patent: July 25, 2023Assignees: AGV Discovery, Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Universite De MontpellierInventors: Jean-François Guichou, Cédric Bories, Clément Geoffroy, Charline Duquenne, Muriel Gelin, Gilles Labesse, Yannick Bessin, Loic Mathieu
-
Patent number: 11702671Abstract: An expression vector containing appropriate mitochondrion-targeting sequences (MTS) and appropriate 3?UTR sequences provides efficient and stable delivery of a mRNA encoding a protein (CDS) to the mitochondrion of a mammalian cell. The MTS and 3?UTR sequences guide the CDS mRNA from the nuclear compartment of the cell to mitochondrion-bound polysomes, where the CDS is translated. This provides an efficient translocation of a mature functional protein into the mitochondria. A method of targeting mRNA expressed in the nuclear compartment of a mammalian cell to the mitochondrion is also provided. The vector and methods can be used to treat defects in mitochondrial function.Type: GrantFiled: May 26, 2021Date of Patent: July 18, 2023Assignee: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Marisol Corral-Debrinski, Jose-Alain Sahel, Valerie Kaltimbacher, Crystel Bonnet
-
Publication number: 20230220480Abstract: The invention relates to the use of an iron-score based on the expression level of at least 2 genes, in particular at least 5, preferably at least 10, and even preferably 11 genes selected in the group consisting of ALAS1, HIF1A, LRP2, HMOX1, HMOX2, HFE, ISCA1, SLC25A37, PPOX, STEAP1 and TMPRSS6 involved in the iron metabolism, as a prognosis marker in subjects having DLBCL, in particular for identifying subjects with a poor outcome such as a relapse and/or death.Type: ApplicationFiled: November 6, 2020Publication date: July 13, 2023Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), UNIVERSITE DE MONTPELLIER, INSTITUT CURIEInventors: Jérôme MOREAUX, Raphaël RODRIGUEZ, Julie DEVIN, Caroline BRET, Tatiana CANEQUE COBO
-
Patent number: 11697689Abstract: Disclosed is a method for delivery of an anti-cancer agent into a cell expressing the OAcGD2 ganglioside by using an antibody recognizing the OAcGD2 ganglioside.Type: GrantFiled: December 5, 2017Date of Patent: July 11, 2023Assignees: OGD2 PHARMA, NANTES UNIVERSITÉ, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), INSTITUT DE CANCEROLOGIE DE L'OUESTInventors: Stéphane Birkle, Julien Fleurence, Sébastien Faraj, Jean-Marc Le Doussal, Denis Cochonneau, Mickaël Terme, Brigitte Assouline
-
Patent number: 11696579Abstract: The invention relates to a method for increasing the lifespan of animal sperm comprising contacting said sperm with an inhibitor of Slo3 potassium channel. The invention also relates to a use of an inhibitor of Slo3 potassium channel, for increasing the lifespan of animal sperm or motility of capacitated animal sperm, comprising contacting an inhibitor of Slo3 potassium channel with said sperm. Moreover, the invention relates to an artificial insemination instrument for use in artificial insemination of an animal, comprising animal sperm in contact with an inhibitor of Slo3 potassium channel. The invention also relates to a method for artificially inseminating an animal using said artificial insemination instrument. Eventually, the invention relates to a method for increasing the fertility of an animal, comprising contacting sperm of said animal with an inhibitor of Slo3 potassium channel; then artificially inseminating said animal with said sperm.Type: GrantFiled: December 18, 2018Date of Patent: July 11, 2023Assignees: IMV TECHNOLOGIES, UNIVERSITE GRENOBLE ALPES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), SWISSGENETICSInventors: Christophe Arnoult, Eric Schmitt, Guillaume Martinez, Jessica Escoffier
-
Publication number: 20230212231Abstract: The present disclosure provides polypeptides derived from SARS-CoV-2 which have therapeutic use. One such polypeptide is a polypeptide, referred to as “Npep2,” is derived from the SARS-CoV-2 protein N and has at least 50 consecutive amino acids of the amino acid sequence having at least 90% identity with the amino acid sequence that ranges from the residue at position 276 to the residue at position 411 of SEQ ID NO:2. Further described are conjugates wherein a heterologous polypeptide is conjugated or fused to Npep2. The present disclosure further provides vaccines employing the polypeptides, polynucleotides encoding the polypeptides, and methods of vaccinating subjects against SARS-CoV-2 by administering a therapeutically effective amount of one or more of the polypeptides.Type: ApplicationFiled: May 26, 2021Publication date: July 6, 2023Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), Baylor Research Institute, Assistance Publique - Hopitaux de Paris (APHP), Universite Paris Est Creteil Val de MarneInventors: Yves LEVY, Gérard ZURAWSKI, Sandra ZURAWSKI, Christine LACABARATZ, Sylvain CARDINAUD, Mathieu SURENAUD
-
Publication number: 20230203197Abstract: New human therapeutic monoclonal antibodies, which are directed against neutrophil proteinase 3. The monoclonal antibodies are specifically directed against a conformational epitope of the neutrophil proteinase 3 and are capable of inhibiting by at least 30% the production for reactive oxygen derivatives by neutrophils. Also, a pharmaceutical composition including as an active substance at least the monoclonal antibody, and a method for early treatment and/or prevention of relapse of granulomatosis with polyangiitis, which includes the administration of the pharmaceutical composition.Type: ApplicationFiled: October 16, 2020Publication date: June 29, 2023Applicants: UNIVERSITE DE TOUR, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE TOURS, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Roxane LEMOINE, Cyrille HOARAU, Eric MORELLO, Brice KORKMAZ, Yann GALLAIS
-
Publication number: 20230203005Abstract: The present invention relates to the Compound of following formula (I): or a pharmaceutically acceptable salt thereof. The present invention also relates to a pharmaceutical composition containing such a compound and a method for preparing such a compound.Type: ApplicationFiled: March 6, 2023Publication date: June 29, 2023Applicants: UNIVERSITE PARIS-SACLAY, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT GUSTAVE-ROUSSY, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Mouad ALAMI, Olivier PROVOT, Abdallah HAMZE, Ilhem KHELIFI, Timothée NARET, Sébastien APCHER, Romain DARRIGRAND
-
Patent number: 11684640Abstract: The invention relates to gut microbiota profiles associated with response or resistance to treatments with ICB, in particular with anti-PD1 or anti PD-L1 or anti-PD-L2 antibodies. In particular, the invention pertains to a theranostic method for identifying good responders, to whom an anti-PD1 or anti PD-L1 or anti-PD-L2 can be administered, while a pre-treatment based on FMT and/or immunogenic probiotics is recommended to bad responders exhibiting a dysbiosis. In particular, the present invention pertains to Akkermansia muciniphila as the main commensal species distinguishing responders from progressors and its use alone or with E. hirae for the treatment of antibiotics or gut repertoire insufficiency-associated dysbiosis.Type: GrantFiled: December 22, 2017Date of Patent: June 27, 2023Assignees: INSTITUT GUSTAVE ROUSSY, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM, UNIVERSITE PARIS-SACLAY, Insitut national de recherche pour l'agriculture, l'alimentation et l'environnement (INRAE)Inventors: Laurence Zitvogel, Bertrand Routy, Emmanuelle Le Chatelier
-
Patent number: 11684633Abstract: A method is provided for preventing and/or treating heart failure in a subject in need thereof by administering to the subject a therapeutically effective amount of polydextrose. The method may also include the use of polydextrose for preventing cardiac remodeling and/or ventricle dilatation and/or for preventing systolic dysfunction, as well as preventing an increase in bacterial translocation to heart tissue in a subject who suffered from a myocardial infarction.Type: GrantFiled: January 5, 2021Date of Patent: June 27, 2023Assignees: VAIOMER, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Christophe Heymes, Rémy Burcelin, Benjamin Lelouvier, Jacques Amar
-
Patent number: 11680245Abstract: Innate lymphoid cells (ILCs) represent innate versions of T helper and cytotoxic T cells that differentiate from committed ILC precursors (ILCP). Still, how ILCP relate to mature tissue-resident ILCs remains unclear. ILCP that are present in the blood and all tested lymphoid and non-lymphoid human tissues were identified. Human ILCP fail to express the signature transcription factors (TF) and cytokine outputs of mature NK cells and ILCs but are epigenetically poised to do so. Human ILCP robustly generate all ILC subsets in vitro and in vivo. While human ILCP express RAR related orphan receptor C (RORC), circulating ILCP can be found in RORC-deficient patients that retain potential for EOMES+ NK cells, T-BET+ ILC1, GATA-3+ ILC2 and for IL-22+ but not for IL-17A+ ILC3. A model of tissue ILC differentiation (‘ILC-poiesis’) is proposed whereby diverse ILC subsets are generated in situ from ILCP in response to environmental stressors, inflammation and infection.Type: GrantFiled: November 30, 2017Date of Patent: June 20, 2023Assignees: INSTITUT PASTEUR, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: James Di Santo, Ai Ing Lim